Skip to main content
TipRanks
Go Ultimate75% OFF

Aligos Therapeutics (ALGS) Financial Statements

500 Followers

Aligos Therapeutics Financial Overview

Aligos Therapeutics's market cap is currently $18.11M. The company's EPS TTM is $-6.35; its P/E ratio is -0.34; Aligos Therapeutics is estimated to report earnings on March 11, 2027, and the estimated EPS forecast is $-2.00. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 2.19M$ 3.94M$ 15.53M$ 13.91M$ 4.36M
Gross Profit$ 1.26M$ 3.94M$ 15.53M$ 13.91M$ 4.36M
Operating Income$ -87.98M$ -89.15M$ -88.13M$ -97.58M$ -128.32M
EBITDA$ -22.95M$ -128.26M$ -83.81M$ -92.27M$ -124.41M
Net Income$ -24.19M$ -131.21M$ -87.68M$ -96.05M$ -128.33M
Balance Sheet
Cash & Short-Term Investments$ 77.84M$ 56.94M$ 135.70M$ 125.83M$ 190.73M
Total Assets$ 88.53M$ 70.09M$ 151.53M$ 146.69M$ 235.37M
Total Debt$ 5.25M$ 8.38M$ 11.14M$ 12.57M$ 14.46M
Net Debt$ -13.05M$ -28.62M$ -124.57M$ -68.77M$ -172.36M
Total Liabilities$ 34.99M$ 99.07M$ 59.45M$ 42.79M$ 50.64M
Stockholders' Equity$ 53.55M$ -28.97M$ 92.08M$ 103.90M$ 184.73M
Cash Flow
Free Cash Flow$ -82.94M$ -80.87M$ -79.02M$ -80.33M$ -116.55M
Operating Cash Flow$ -82.50M$ -80.74M$ -79.00M$ -79.39M$ -115.66M
Investing Cash Flow$ -37.83M$ -18.28M$ 44.98M$ -26.29M$ 3.02M
Financing Cash Flow$ 101.64M$ 355.00K$ 88.33M$ 164.00K$ 78.68M

Currency in USD

Aligos Therapeutics Earnings and Revenue History

-160M-80M080M-3600 %-2400 %-1200 %0 %EarningsProfit Margin20182019202020212022202320242025RevenueEarningsProfit Margin

Aligos Therapeutics Liabilities to Assets

0100M200M300M0 %60 %120 %180 %LiabilitiesLiabilities to Assets20182019202020212022202320242025AssetsLiabilitiesLiabilities to Assets

Aligos Therapeutics Cash Flow

-200M-100M0100M200M300M20182019202020212022202320242025OperatingInvestingFinancing

Aligos Therapeutics Forecast EPS vs Actual EPS

-4-3-2-101Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26EPS EstimateBeatMiss